EPIDAURUS
prasugrel or ticagrelor with a DOAC after infarction in atrial fibrillation triples major bleeding, the trial was stopped early
Randomised trial stopped early for safety after 602 of 1,474 planned patients with AF and myocardial infarction: DOAC plus one month of prasugrel or ticagrelor versus DOAC plus clopidogrel (with in-hospital aspirin). BARC 3 or higher bleeding HR 3.54 (95% CI 1.15 to 10.85, p=0.028) within six weeks, with no difference in ischaemic outcomes at six weeks or six months. Presented by Konstantinos Rizas (LMU Munich) in Hot Line 3, Nature Medicine.
